Delcath Systems Inc. (DCTH)
| Bid | 11.7 |
| Market Cap | 419.21M |
| Revenue (ttm) | 37.11M |
| Net Income (ttm) | -27.53M |
| EPS (ttm) | -0.93 |
| PE Ratio (ttm) | -13.49 |
| Forward PE | -216.08 |
| Analyst | Strong Buy |
| Ask | 13.17 |
| Volume | 406,832 |
| Avg. Volume (20D) | 444,073 |
| Open | 12.63 |
| Previous Close | 12.73 |
| Day's Range | 12.18 - 12.83 |
| 52-Week Range | 4.26 - 16.97 |
| Beta | 0.82 |
About DCTH
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial fo...
Analyst Forecast
According to 4 analyst ratings, the average rating for DCTH stock is "Strong Buy." The 12-month stock price forecast is $22.5, which is an increase of 79.28% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago · businesswire.com
Delcath Systems Reports Fourth Quarter and Full Year 2024 ResultsQUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of t...
